ReviewCell communication and signaling : CCS2026
Extracellular matrix polysaccharides and glycoproteins in ovarian cancer: structural-functional macromolecular perspectives and potential exosome-derived biomarkers.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) remains a formidable challenge in oncology due to its high lethality. This poor prognosis is driven primarily by insidious peritoneal metastasis and the rapid development of resistance to conventional therapies. This comprehensive review delves into the transformative roles of extracellular matrix (ECM) polysaccharides and glycoproteins as dynamic architects of the tumor microenvironment (TME), reshaping our understanding of OC progression from a macromolecular lens. We elucidate how structural modifications—such as the enzymatic fragmentation of hyaluronan (HA) into pro-invasive low-molecular-weight forms, aberrant cross-linking of fibrous glycoproteins via lysyl oxidases, and dysregulated proteoglycans like biglycan (BGN) and versican—orchestrate a shift from physiological homeostasis to a stiffened, pro-malignant scaffold that fuels cell adhesion, invasion, and immune evasion. Central to this narrative is the emerging paradigm of tumor-derived exosomes as masterful conductors of ECM remodeling. These nanoscale vesicles ferry a potent cargo of proteases (e.g., matrix metalloproteinases, MMPs), microRNAs, and glycoprotein fragments, systematically priming distant pre-metastatic niches and amplifying systemic dissemination. By integrating biophysical insights, enzymatic mechanisms, and vesicular communication, we highlight novel interconnections that propel OC aggressiveness.Looking forward, we spotlight the translational promise of exosome-encapsulated macromolecular signatures—ranging from unique glycosignatures and BGN fragments to innovative diagnostic panels like the Ovarian Cancer Score (OCS)—as ultrasensitive liquid biopsy biomarkers. These advancements pave the way for early detection, precise prognostication, and tailored interventions, offering hope to combat this devastating disease. This review not only synthesizes cutting-edge evidence but also charts future directions for harnessing ECM-exosome dynamics in breakthrough therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.